Medication safety in patients treated with new oral antitumor agents: A prospective, randomized investigation on the impact of intensified clinical pharmaceutical/clinical pharmacological care on patient safety, patient knowledge and patient well-being (AMBORA). Supported by the German Cancer Aid within the Comprehensive Cancer Center Erlangen-EMN (2018) Schlichtig K, Lechner P, Grafe C, Ferstl B, Fuchs F, Hein A, Meidenbauer N, et al. Conference contribution Radiation and checkpoint Blockade in the treatment of metastases (2018) Hirschmann E, Gaipl U, Fietkau R, Distel L, Hecht M Conference contribution Predictive character of peripheral blood immunophenotype before and during treatment with PD-1 immune checkpoint inhibitors (interim analysis of the prospective phase IV ST-ICI trial) (2018) Hecht M, Harrer A, Rutzner S, Lettmaier S, Wolf W, Fietkau R, Frey B, Gaipl U Conference contribution Significance of altered PD-L1 expression in tumor tissue of oral squamous cell carcinomas (2018) Weber M, Wehrhan F, Baran C, Agaimy A, Buettner-Herold M, Preidl R, Neukam FW, Ries J Conference contribution Managing toxicities of immunotherapies - a side effect register for rare and severe side effects of checkpoint Inhibitor therapy (2018) Heinzerling L, Schuler G Conference contribution PD-L1 expression in peripheral blood samples of patients with oral squamous cell carcinomas (2018) Ries J, Weber M, Baran C, Agaimy A, Buettner-Herold M, Preidl R, Neukam FW, Wehrhan F Conference contribution Multidisciplinary Late Effects Clinics for Childhood Cancer Survivors in Germany - a Two-Center Study (2018) Gebauer J, Rieken S, Schuster S, Hahn B, Gebauer N, Meidenbauer N, Brabant G, et al. Journal article Potential role of the PD-1/PD-L1 axis in the immune regulation of chronic GVHD (2017) Klobuch S, Weber D, Holler B, Herr W, Holler E, Wolff D Journal article Prognostic factors for overall survival of patients with advanced renal cell carcinoma - data from the German prospective RCC-Registry (2017) Goebell P, Mueller L, Staehler M, Mueller M, Frank M, Kruggel L, Jaenicke M, Marschner N Conference contribution Real world effectiveness and safety of pazopanib and everolimus in metastatic renal cell carcinoma: first interim analysis of the PAZOREAL study (2017) Bedke J, Welslau M, Boegemann M, Schostak M, Hering-Schubert C, Petzoldt A, Wolf T, et al. Conference contribution